New minor groove covering DNA binding mode of dinuclear Pt(II) complexes with various pyridine-linked bridging ligands and dual anticancer-antiangiogenic activities

Franich, Andjela A.; Živković, Marija D.; Ilić-Tomič, Tatjana; Đorđević, Ivana; Nikodinović‐Runić, Jasmina; Pavić, Aleksandar; Janjić, Goran V.; Rajković, Snežana

doi:10.1007/s00775-020-01770-7

Cited by 20 publications

(4 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore much research aims at the synthesis of new complexes directed at different targets. The presence of a less labile ligand in the structure of new generation platinum drugs may contribute to the lower toxicity of these compounds, especially neuro- and nephron- toxicity, while maintaining the same, and in some cases greater, antitumor activity [ 17 , 18 ]. The compounds synthesized by our team seem to confirm this thesis.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of the Anticancer Activities of Novel Transition Metal Complexes with Berenil and Nitroimidazole

et al. 2020

View full text Add to dashboard Cite

Novel transition metal complexes (Au, Pd, Pt) with berenil and 2-(1-methyl-5-nitroimidazol-2-yl)ethanol were obtained through two-step synthesis. The cytotoxicity assay against MCF-7 and MDA-MB-231 breast cancer cells revealed that novel platinum and palladium complexes cause a reduction on the viability of MCF-7 and MDA-MB-231 breast cancer cells to a greater extent than cisplatin. The complexes showed lower cytotoxicity on normal MCF-10A human breast epithelial cells than on tumor cells. Furthermore, we observed that these complexes selectively concentrate in tumor cell mitochondria due to the characteristic for these cells increased membrane potential that may explain their increased proapoptotic activity. The activity of the synthesized compounds against topoisomerase type IIα and their increased impact on DNA defragmentation also were documented. The novel complexes also induced autophagosome changes and inhibited tumor growth in xenograft models (established using breast cancer cells).

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluation of the Anticancer Activities of Novel Transition Metal Complexes with Berenil and Nitroimidazole

et al. 2020

View full text Add to dashboard Cite

show abstract

“…A large therapeutic window was demonstrated, which is highly beneficial for cancer treatment. The study revealed that novel binuclear Pt(II) complexes may be new, effective, and safe anticancer agents [ 33 ].…”

Section: Modifications Of Platinum- and Palladium-based Moleculesmentioning

confidence: 99%

Platinum and Palladium Complexes as Promising Sources for Antitumor Treatments

Czarnomysy

Radomska

Szewczyk

et al. 2021

IJMS

View full text Add to dashboard Cite

There is a need for new, safer, and more effective agents to treat cancer. Cytostatics that have transition metals at their core have attracted renewed interest from scientists. Researchers are attempting to use chemotherapeutics, such as cisplatin, in combination therapy (i.e., in order to enhance their effectiveness). Moreover, studies are being carried out to modify molecules, by developing them into multinuclear structures, linking different compounds to commonly used drugs, or encapsulating them in nanoparticles to improve pharmacokinetic parameters, and increase the selectivity of these drugs. Therefore, we attempted to organize recent drug findings that contain palladium and platinum atoms in their structures.

show abstract

“…However, some complexes do not possess a specific targeting group, but still show antiangiogenic activity. For example, dinuclear complexes 27-29 ( Figure 11) were found to interact with the phosphate backbone, forming Pt-DNA adducts with a minor groove covering [91]. These complexes, particularly complex 27, are potential chemotherapeutics with anticancer and antiangiogenic activities, and no toxic effects at the desired concentration.…”

Section: Targeted Monofunctional Pt II Complexesmentioning

confidence: 99%

Monofunctional Platinum(II) Anticancer Agents

Jin

Guo

et al. 2021

Pharmaceuticals

View full text Add to dashboard Cite

Platinum-based anticancer drugs represented by cisplatin play important roles in the treatment of various solid tumors. However, their applications are largely compromised by drug resistance and side effects. Much effort has been made to circumvent the drug resistance and general toxicity of these drugs. Among multifarious designs, monofunctional platinum(II) complexes with a general formula of [Pt(3A)Cl]+ (A: Ammonia or amine) stand out as a class of “non-traditional” anticancer agents hopeful to overcome the defects of current platinum drugs. This review aims to summarize the development of monofunctional platinum(II) complexes in recent years. They are classified into four categories: fluorescent complexes, photoactive complexes, targeted complexes, and miscellaneous complexes. The intention behind the designs is either to visualize the cellular distribution, or to reduce the side effects, or to improve the tumor selectivity, or inhibit the cancer cells through non-DNA targets. The information provided by this review may inspire researchers to conceive more innovative complexes with potent efficacy to shake off the drawbacks of platinum anticancer drugs.

show abstract

New minor groove covering DNA binding mode of dinuclear Pt(II) complexes with various pyridine-linked bridging ligands and dual anticancer-antiangiogenic activities

Cited by 20 publications

References 57 publications

Evaluation of the Anticancer Activities of Novel Transition Metal Complexes with Berenil and Nitroimidazole

Evaluation of the Anticancer Activities of Novel Transition Metal Complexes with Berenil and Nitroimidazole

Platinum and Palladium Complexes as Promising Sources for Antitumor Treatments

Monofunctional Platinum(II) Anticancer Agents

Contact Info

Product

Resources

About